BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a Healthcare company (Biotechnology) with a market capitalization of $11.1B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), BioMarin Pharmaceutical Inc. had a Maz Rating of 4.37 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.83), among the strongest in its sector; its weakest was Valuation (2.42), more expensive than most of its sector. The other factors: Financial Health 4.60 (among the strongest in its sector); Growth 3.43 (around the middle of its sector); Momentum 3.04 (around the middle of its sector). The current rating is for members: log in to see it.
At $57.18, BioMarin Pharmaceutical Inc. trades at 3.0x sales and 1.8x book value, with an EV/EBITDA of 32.6. Over the last twelve months it generated about $3.7B of revenue and a net loss of $17M. It runs a gross margin of 75.4%, an operating margin of 6.5% and a net margin of -0.5%. It shows return on equity of -0.3%, return on invested capital of -1.0% and a free cash flow yield of 5.0%. On the balance sheet: a debt-to-equity ratio of 0.67 and a current ratio of 2.44. Over the past 52 weeks the share price ranged from $49.26 to $70.98, with a beta of 0.21.
BioMarin Pharmaceutical Inc. does not currently pay a dividend.
41 Wall Street analyst ratings cover the stock: 29 Buy and 12 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.